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Abstract  
This paper examines the changes in firms’ innovation performance around initial public 
offerings (IPO) and mergers and acquisitions (M&A) using innovation data based on patent 
applications, new product introductions, and scientific article publications. The quantity of 
innovation is measured by number of innovative outputs and the quality of innovation is 
measured by a variety of metrics including patent or article citation count and content-based 
novelty score. Results generally show that innovation quantity increases while innovation quality 
declines following IPO and M&A events. The findings are consistent among patent-based, 
product-based, and publication-based metrics, and confirm with the results from previous 
literature. In addition, innovation performance is found to vary with financial performance and 
industry characteristics. Firms that exhibit larger asset and cash holdings, higher profitability, 
and more R&D investments are in general more innovative in terms of both quality and quantity. 
In post-IPO or post-M&A years, higher industry sales concentration and geographic 
concentration tend to correlate with lower innovation quantity and higher innovation quality. 
This paper also attempts to study the mobility of innovative employees around IPO and M&A, 
but the results lack sufficient insights on whether the observed post-event decline in innovation 
quality can be explained by changes in the composition of innovators. Overall, despite the ability 
to produce more innovations after going public or acquiring another company, firms should be 
mindful of the potential loss in innovation quality.  
Keywords: innovation, IPO, M&A, industry characteristics, financial performance, innovator 
mobility   
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1. Introduction and Literature Review 
The quality of innovation is essential to a firm’s long-term performance, as innovative 
activities can not only enhance a firm’s competitiveness in the market, but also generate positive 
externalities for the society through the introduction of new technologies. According to the U.S. 
Department of Commerce (2007), innovation is “the design, invention, development and/or 
implementation of new or altered products, services, processes, systems, organizational 
structures, or business models for the purpose of creating new value for customers and financial 
returns for the firm.” In other words, innovation needs to be both novel and commercially 
valuable. Literature on firm innovation has suggested that innovation capability is the most 
important determinant of firm performance and that higher innovativeness is related to better 
firm performance in terms of return on investment and profitability (Calantone, Cavusgil, and 
Zhao 2002). Despite the importance of innovation to corporate performance, it is oftentimes 
difficult for firms to maintain innovation capability over time, especially after firms experience 
substantial strategic changes such as initial public offerings (IPO) and mergers and acquisitions 
(M&A). It is likely that IPO and M&A events will impact a firm’s innovation strategy and 
thereafter lead to changes in innovation performance.    
There has been a large amount of research that investigates how general firm 
performance changes around IPO and M&A. Studies have shown that there is significant post-
IPO deterioration in firms’ operational and financial performance (Jain and Kini 1994). On the 
M&A side, mixed views have emerged on whether post-M&A performance of the combined 
firm improves or declines, with some scholars finding that long-term operational and financial 
performance of M&A activities depend on various factors such as size of the target firm and 
incentive compensation plans (Ramaswamy and Waegelein 2003).  
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It wasn’t until recently that researchers have started to specifically link innovation, the 
most crucial driver of firm performance, with IPO and M&A events. While firms invest in 
innovation primarily through research and development (R&D) expenditures, many scholars 
have illustrated that R&D is not a reliable measure of innovation, as R&D only captures one 
observable input of innovation and does not account for other observable and unobservable 
aspects such as talent allocation and incentive compensation plans (He and Tian 2013). The most 
popular measure of innovation among scholars is patent information. Patent-based metrics are 
found to be more economically meaningful than R&D as they not only convey the strength of a 
firm’s intellectual property but also provide insights into the firm’s market value (Hall, Jaffe, and 
Trajtenberg 2005; Bernstein 2015). Scholars who utilize patent data in general find that the 
quality of innovation, as measured by the number of patent citations, tends to decrease following 
IPO activities due to short-termism – the pressures from shareholders to increase short-term 
earnings (Bernstein 2015; He and Tian 2013). In terms of innovation strategy, private firms tend 
to be more exploratory and rely more on existing knowledge while public firms are more 
exploitative and more likely to invest in new technologies (Gao, Hsu, and Li 2018). In terms of 
M&A, scholars have also applied patent-based metrics to explore the relationship between 
innovative activities and M&A considerations and discovered that post-merger innovation 
performance increases when there is a reasonable pre-M&A overlap between the technologies of 
the acquirer firm and those of the target firm (Bena and Li 2014; Cloodt, Hagedoorn, and 
Kranenburg 2006). One study also concludes that the quality of firm innovation is highest under 
private ownership, intermediate under M&A, and lowest under public ownership, based on 
patent data of VC-backed biotech firms (Aggarwal and Hsu 2013).  
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While there is already a moderate amount of research on the relationship between 
innovation performance and strategic activities in recent years, most of existing literature uses 
patent data as a proxy for innovation. Although scholars have illustrated the reliability of patent-
based measurement of innovation (Hall, Jaffe, and Trajtenberg 2005; Bernstein 2015), this 
practice may still lack sufficient content validity as patenting is only one way to create 
innovation. Firms may also choose to innovate through academic publications, new product 
introductions, as well as other activities that are not patented or have not been patented yet. 
Several studies have adopted measures other than patent data to analyze firm innovation 
performance. Murray and Stern (2007) discover that innovation leads to both scientific 
publications and patent grants, with publications pre-dating patent grants and publication 
citations declining following patent grants. Moreover, Wies and Moorman (2015) measure firm 
innovation using new product introductions and find that public firms in the consumer-packaged 
goods industry show increased innovation level but decreased innovation riskiness compared to 
private firms. Despite the variety of innovation measures, application of simply one particular 
metric may still fail to provide a comprehensive image of a firm’s innovation performance.  
In addition to the lack of content validity in selecting proxy for innovation, most of the 
existing research also takes a very broad approach to assess innovation performance, which 
speaks to quantity of innovation and quality of innovation. While quantity can be measured in a 
straightforward way through counting the number of innovation outputs, the quality or degree of 
novelty of each innovation is harder to operationalize. The existing literature has largely used the 
number of citations a patent receives to measure innovation quality. According to Bernstein 
(2015), the citation count metric is capable of distinguishing between breakthrough innovation 
and incremental innovation as it reflects the importance other inventors place on the particular 
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patent. However, citation count may not provide sufficient criterion validity since this metric 
only reflects the number of times an innovation is cited without looking into the specific content 
of the innovation output. It is possible that inventors from other firms are not citing the core idea 
in the patent, or that the patent is contributing an incremental idea to an existing field rather than 
putting forward a breakthrough idea.      
 
2. Research Question and Hypotheses 
This paper aims to contribute to existing literature on firm-level innovation performance 
and how it relates to strategic decisions. I intend to address the lack of content and criterion 
validity in innovation measurement by examining various innovation modes and innovation 
metrics to present a more thorough analysis of firm innovation performance. I study three modes 
of innovation – patent applications, new product introductions, and scientific publications – and 
explore how each innovation mode relates to IPO and/or M&A activities. When selecting metrics 
to measure the quantity and quality of innovation, in addition to the traditional metrics such as 
number of innovation outputs and number of citations, I also use other metrics that are derived 
from the specific content of each innovation output. Text mining of innovative content should 
allow for a more in-depth examination of innovation quality than simply counting the number of 
citations. For example, in analyzing scientific publications data, I assign an innovation novelty 
score for each published scientific article through calculating the average age of non-stop words 
in the abstract of the article.      
This paper also attempts to explore possible reasons behind changes in innovation 
performance around IPO and M&A activities. While shareholder pressure for short-term 
earnings is widely regarded by the literature as a key reason for lower innovation quality of 
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public firms (Bernstein 2015; He and Tian 2013; Asker, Farre-Mensa, and Ljungqvist 2014), 
innovator mobility may also explain this phenomenon as innovators are the main employees 
responsible for producing innovation output and they may leave or stay following the firm’s 
strategic initiatives due to changes in organizational culture and incentive compensation plans 
(Bernstein 2015). This paper focuses on exploring the mobility of scientific publication authors 
around IPO and M&A activities. Additionally, innovation dynamics can also vary across 
industries due to the impact of different structural forces and differ across firms that exhibit 
distinct levels of financial performance. Thus, industry characteristics (sales concentration, 
turbulence or instability, geographic concentration) and financial metrics (total assets, net 
income, cash, R&D investments) are also examined as potential factors that may affect 
innovation performance around strategic activities.  
 
 
 
3. Datasets 
There are two pillars of data used in this paper. The first pillar includes data on firm-level 
innovative activities. Three categories of innovation data will be examined: patent applications, 
new product introductions, and scientific publications. The second pillar of data in the paper is 
firm-level strategic and financial information, including IPO and M&A dates and financial 
metrics. 
A. Patent Data 
Raw patent data is obtained from the patent database of the National Bureau of Economic 
Research (NBER), which contains more than three million patents filed to the United States 
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Patent and Trademark Office (USPTO) from 1976 to 2006 (Hall, Jaffe, and Trajtenberg 2001). 
The database is publicly available and includes the patents filed by each firm to USPTO as well 
as the number of citations, originality metric, and generality metric of each patent. The NBER 
database also contains matching of firm names in the USPTO database with GVKEY (a unique 
firm identifier) used by the Compustat financial information database so that I can match each 
firm’s patent applications with its IPO status and other financial metrics.      
B. Product Introductions Data 
Data for new product introductions is gathered from the FactSet Revere database 
available on Wharton Research Data Services (WRDS). The dataset houses information on new 
product launches of all firms covered by FactSet since 2003. In addition to the dates of the firms’ 
product launches, the database also contains each product’s sector description as well as CUSIP 
firm identifiers for matching to the Compustat database.     
C. Scientific Publications Data 
Data for scientific publications is obtained from the Elsevier's Scopus database, which is 
the largest abstract and citation database of peer-reviewed literature. For each firm in my patent 
universe that is also included by Scopus, I collect basic publication information, such as topic 
and year, citation frequency, and author affiliations, as well as full abstracts of all articles 
published by the firm. Because Scopus does not contain unique identifiers for firm names, I input 
firm names into Scopus’ web search query to download basic publication information and then 
match the firm names in the downloaded data to GVKEY identifiers. Article abstracts are 
downloaded from a combination of Scopus web searches and Scopus Abstract Retrieval API. I 
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use PyScopus, a Python wrapper for Scopus API developed by Zuo, Zhao, and Eichmann (2017), 
and employ the Abstract Retrieval API to obtain abstracts by Scopus ID, which is a unique 
article identifier.  
For both product introductions and scientific publications data, I focus on firms that 
overlap with my patent universe so that I can compare the analytical results from product-based 
and publication-based metrics with those from patent-based metrics.   
D. Firm-Level Strategic and Financial Information  
Most of the data on firm-level strategic and financial information comes from the 
Compustat North America database available on WRDS. Compustat contains U.S. and Canadian 
fundamental information of both active and inactive publicly-traded companies since 1950. For 
IPO events, I gather data items including IPO year, industry classification, and financial metrics 
of all firms in my universe from Compustat. Industry classification is indicated by the Standard 
Industry Classification (SIC) code which is a widely-used system for classifying firms into 
industry areas. Firm financial metrics include natural logarithm of total assets (Log Total 
Assets), ratio of R&D to total assets (R&D / Total Assets), ratio of net income to total assets (Net 
Income / Total Assets), and ratio of cash to total assets (Cash / Total Assets). Then, I combine 
data from each of the three innovation categories with IPO years, industry codes, and financial 
metrics.     
For M&A events, I use the Thomson Reuters SDC database on WRDS which houses 
information on M&A transactions of public firms since 1965. To construct a relevant sample of 
M&A transactions, I follow the sample selection treatment by Bena and Li (2014). I include an 
M&A transaction only if the acquirer is seeking to own more than 50% of the target firm and 
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owns at least 90% of the target firm after deal completion. In addition, the target firm's total 
assets must be valued at more than $1 million and neither the acquirer nor the target firm is a 
financial institution. Then, I combine data from each innovation category with M&A years, 
industry codes, and financial metrics.      
 
4. Research Methodology and Results   
My analysis mainly consists of two parts. I first run a series of Ordinary Least Squares 
(OLS) linear regression analyses on the relationship between innovation performance and IPO or 
M&A status based on patent data, product introductions data, and scientific publications data, 
respectively. Following Bernstein (2015), I consider innovation performance from three years 
before (-3) to five years after (+5) IPO or M&A events. I also control for industry characteristics 
and financial metrics that may relate to change in innovation performance around IPO and M&A 
events. The variables for industry characteristics include sales concentration, market turbulence, 
and geographic concentration, and the variables for financial metrics include natural logarithm of 
total assets, ratio of R&D to total assets, ratio of net income to total assets, and ratio of cash to 
total assets. After examining the relationship between innovation performance and IPO or M&A 
status, I explore innovator mobility around IPO and M&A activities based on author information 
of firms’ scientific publications in order to analyze whether innovator mobility could be a 
potential reason for the observed innovation changes around strategic events. 
 
A. Changes in Innovation around IPO and M&A Events  
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i. Changes in innovation around IPO based on patent metrics 
Following Bernstein (2015), I first explore the relationship between patent-based 
innovation metrics and IPO activities. Table 1 in the Appendix shows summary statistics for the 
patent applications of firms from three years before to five years after IPO events. My dataset 
includes 2,409 firms and 90,338 patent-firm-year observations. Patent applications are 
concentrated in Computers and Communication, Drugs and Medicine, and Electronics industries. 
Moreover, the mean number of patents increased for firms after they went public, but the mean 
number of citations decreased. This seems to confirm with Bernstein (2015) that firms engaged 
in higher number of innovations after IPO but the quality of innovation decreases.     
For dependent variables, I use various patent-based metrics for innovation performance. 
Innovation quantity is measured by patent count (number of patents of each firm). Innovation 
quality is measured in three ways: citation count (number of times each patent is cited), 
generality (degree to which a patent is cited by patents from a more diverse range of technology 
classes), and originality (degree to which a patent is citing a broader set of technology classes). 
In order to mitigate skewness in the distribution of patent and citation counts, we use the natural 
logarithm of patent counts and the natural logarithm of citations counts. To avoid any zero 
values, I add one to the patent count or citation count when taking the natural logarithm. 
The primary independent variable is IPO status, which is a dummy variable that goes 
from -3 to +5, representing 3 years before to 5 years after an IPO event. The coefficients for the 
dummy variables are with respect to the year of IPO (year 0). I also include industry sales 
concentration, industry turbulence, and industry geographic concentration which may also relate 
to innovation performance. Industry sales concentration is measured by the Herfindahl-
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Hirschman index (HHI), which is the sum of squared market shares of all firms in an industry in 
a year. In order to ensure that my industry classification is neither too broad nor too narrow in 
the calculation of HHI, I use three-digit SIC codes. The universe of an entire industry is the set of 
all firms belonging to the three-digit SIC code classification in the Compustat North America 
database. In order to calculate the total sales of each three-digit-SIC industry in a specific year, I 
ignore differences between fiscal year and calendar year and assume that each firm generated the 
reported sales amount in the calendar year. Industry turbulence is calculated according to 
Matraves and Rondi (2007), who measure the instability of the market share of the top five firms 
in each industry over time. Geographic concentration of an industry is calculated using the EGI 
index based on Dumais, Ellison, and Glaeser (2002) who measure the degree to which an 
industry is geographically concentrated based on the state-level location of firms in the industry. 
While Dumais, Ellison, and Glaeser (2002) measure industry market share using employment 
data, I substitute sales revenue for employment. The formulas for the calculation of the three 
industry metrics are as follows. 
𝐻𝐻𝐼 = ∑ 𝑠𝑖
2𝑁
𝑖=1 , where si is the sales market share of firm i in the three-digit-SIC 
industry and N is the total number of firms within that industry. 
𝑇𝑢𝑟𝑏𝑢𝑙𝑒𝑛𝑐𝑒 =  1 − 
𝑂𝑡+1
𝑁𝑡+1
 . I first identify the top 5 firms in each industry in 
terms of sales revenue at time 𝑡, then 𝑂𝑡+1 is the cumulative squared market 
shares of the same old 5 firms at time 𝑡 + 1, and 𝑁𝑡+1 is the cumulative squared 
market shares of the actual top 5 firms at time 𝑡 + 1. 
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𝐸𝐺𝐼 =
𝐺𝑖𝑡/(1−∑ 𝑠𝑠𝑡
2 )−𝐻𝐻𝐼𝑠
1−𝐻𝐻𝐼
, where 𝑠𝑖𝑠𝑡 is the share of industry 𝑖’s time 𝑡 sales in state 
𝑠; 𝑠𝑠𝑡 is the state’s share of sales in the average industry; 𝐺𝑖𝑡 is the sum of squared 
deviations of 𝑠𝑖𝑠𝑡 from 𝑠𝑠𝑡; and 𝐻𝐻𝐼 is the Herfindahl-Hirschman index. 
 
In addition to industry characteristics, I also incorporate firm financial metrics, including 
natural logarithm of total assets (Log Total Assets), ratio of R&D to total assets (R&D / Total 
Assets), ratio of net income to total assets (Net Income / Total Assets), and ratio of cash to total 
assets (Cash / Total Assets).    
Based on these dependent and independent variables, I conduct regression analyses with 
firm and year fixed effects to study how patent-based metrics evolve from -3 to +5 years around 
IPO events. As such, the OLS equation I use is as follows:  
𝑌𝑖 = 𝛽0 + ∑ 𝛽𝑛𝐼𝑃𝑂_𝑆𝑡𝑎𝑡𝑢𝑠𝑖
8
𝑛=1
+ 𝛽9𝐻𝐻𝐼𝑖 + 𝛽10𝑇𝑢𝑟𝑏𝑢𝑙𝑒𝑛𝑐𝑒𝑖 + 𝛽11𝐸𝐺𝐼𝑖
+ 𝛽12𝐿𝑜𝑔_𝑡𝑜𝑡𝑎𝑙_𝑎𝑠𝑠𝑒𝑡𝑠𝑖 + 𝛽13𝑁𝑒𝑡_𝑖𝑛𝑐𝑜𝑚𝑒_𝑡𝑜_𝑡𝑜𝑡𝑎𝑙_𝑎𝑠𝑠𝑒𝑡𝑠𝑖
+ 𝛽14𝐶𝑎𝑠ℎ_𝑡𝑜_𝑡𝑜𝑡𝑎𝑙_𝑎𝑠𝑠𝑒𝑡𝑠𝑖 + 𝛽15𝑅&𝐷_𝑡𝑜_𝑡𝑜𝑡𝑎𝑙_𝑎𝑠𝑠𝑒𝑡𝑠𝑖
+ 𝛽16(𝐼𝑃𝑂𝑖
𝑃𝑜𝑠𝑡 ∗ 𝐻𝐻𝐼𝑖) + 𝛽17(𝐼𝑃𝑂𝑖
𝑃𝑜𝑠𝑡 ∗ 𝑇𝑢𝑟𝑏𝑢𝑙𝑒𝑛𝑐𝑒𝑖)
+ 𝛽18(𝐼𝑃𝑂𝑖
𝑃𝑜𝑠𝑡 ∗ 𝑇𝑢𝑟𝑏𝑢𝑙𝑒𝑛𝑐𝑒𝑖) + 𝜀𝑖 
𝑌 represents the innovation performance metric, and 𝐼𝑃𝑂_𝑆𝑡𝑎𝑡𝑢𝑠 is a dummy variable 
showing the firm’s status with respect to its IPO year (𝐼𝑃𝑂 − 3 means the firm is three years 
ahead of its IPO year). 𝐼𝑃𝑂𝑖
𝑃𝑜𝑠𝑡  is equal to 1 if the firm is already past its IPO year, and 
 
 
16 
𝐼𝑃𝑂𝑖
𝑃𝑜𝑠𝑡 ∗ 𝐻𝐻𝐼𝑖   represents the interaction between HHI and post-IPO status. The same notation 
applies to 𝐼𝑃𝑂𝑖
𝑃𝑜𝑠𝑡 ∗ 𝑇𝑢𝑟𝑏𝑢𝑙𝑒𝑛𝑐𝑒𝑖 and 𝐼𝑃𝑂𝑖
𝑃𝑜𝑠𝑡 ∗ 𝐸𝐺𝐼𝑖. 
Results: 
Table 2 of the Appendix shows my analysis on the firm-level change in patent count 
around IPO events, and Table 3 shows the firm-level change in three patent quality metrics – 
average citation count, average generality, and average originality. As shown in Columns (1) and 
(2) of Table 2 and Column (1) of Table 3, innovation in post-IPO years is characterized by 
significantly higher quantity of patents produced but significantly lower citation count. 
Nevertheless, as shown in Columns (2) and (3) of Table 3, most of the coefficients for generality 
and originality metrics are not statistically significant, and the coefficient values do not show a 
consistent pattern as the firm goes from private to public status. In terms of industry 
characteristics, I observe that in post-IPO status, industry sales concentration, turbulence, and 
geographic concentration are in general negatively related to patent count while positively 
related to patent quality metrics.  
In addition, as shown in Column (3) of Table 2, I also conduct another regression 
analysis on patent count by adding four financial metrics variables: natural log of total assets, 
ratio of net income to total assets, ratio of cash to total assets, and ratio of R&D expenditure to 
total assets. The addition of these four independent variables to the regression disrupts the 
increasing trend on patent count with respect to IPO status. Nevertheless, the results suggest that 
firms with higher total assets, higher cash relative to assets, and higher R&D expenditure relative 
to assets tend to produce more innovation outputs. This corresponds to the common consensus 
that firms with more resources tend to have more capacity for innovation. 
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ii. Changes in innovation around M&A based on patent metrics 
Next, I proceed to analyze the change in innovation performance around M&A events. I 
have only considered the innovation performance of acquirer firms, as most target firms would 
disappear following an acquisition. However, some target firms may remain as separate 
subsidiaries of their corresponding acquirer firms after acquisitions, so some patents may be 
assigned to the target firm rather than to the acquirer firm, despite the fact that the innovation 
comes from the acquirer firm as a whole. As such, this analysis may underestimate the 
innovation output following M&A events. Nevertheless, simply adding the patents assigned to 
post-acquisition target firms to the patent set of the parent firms would not work as the Thomson 
SDC database only contains M&A transactions involving public firms. Some public parent firms 
may have acquired private subsidiary firms that operate as a standalone entity in the US patent 
system and do not show up in the patent database.   
My patent-M&A dataset contains 1,462 firms, 2,841 unique M&A transactions, and 
473,023 unique patents. Table 4 in the Appendix exhibits summary statistics of patent 
applications from three years before to five years after M&A transactions. Similar to the patent-
IPO dataset, the Computer and Electronics sectors appear to have the greatest number of patents. 
In addition, the mean number of patents increases in post-M&A years, although the patent count 
data seem to be highly skewed. On the other hand, the average number of patent citations 
decreases following M&A.  
Results:    
I conduct regression analyses with firm and year fixed effects to study how patent-based 
metrics evolve from -3 to +5 years with respect to M&A events. Table 5 of the Appendix shows 
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the change in patent count around M&A events of acquirer firms, and Table 6 shows the change 
in three patent quality metrics – average citation count, average generality, and average 
originality. I obtain similar results as in the IPO case. Innovation in post-M&A years for acquirer 
firms is characterized by higher quantity of patents produced (not significant) but significantly 
lower citation count. In post-M&A years, industry sales concentration is in general negatively 
related to patent count and positively related to patent quality metrics. Moreover, as observed in 
Column (3) of Table 5, higher values of total assets, cash capacity, and R&D expenditure 
correspond significantly to higher patent count.   
 
iii. Changes in innovation around M&A based on product introduction metrics 
Using the same method as in the patent case, I explore the relationship between changes 
in innovation performance and strategic activities based on the product introductions of firms. 
Because the FactSet Revere database primarily covers public firms, there is very limited data on 
the product introductions in the years before the firms went public. As a result, the analysis on 
the innovation changes from three years before to five years after IPO is not robust enough. I 
have decided to remove the analysis on product introductions for the case of IPO.  
Table 7 in the Appendix displays summary statistics of the product introductions of firms 
from three years before to five years after M&A events. The dataset contains 1,222 firms, 2,652 
unique M&A deals, and 72,687 unique product launches. Product launches are concentrated in 
Technology, Healthcare, and Consumer sectors. In addition, I observe that the average number of 
total product introductions is higher while the average number of breakthrough introductions is 
lower during the five years after M&A than during the three years before M&A.    
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The dependent variable for the quantity of product-based innovation is total product 
count (number of product launches). Since there is no equivalent of citation count for product 
launches, I follow Wies and Moorman (2015) to calculate breakthrough product count in order to 
measure the quality of product innovation. Since the FactSet Revere product database includes 
sector specification of each product, I have assigned each product launch to either breakthrough 
(product belonging to a new sector which the associated firm has never been in before) or reuse 
(product belonging to a sector that applies to previous products of the associated firm). As a 
result, the breakthrough product count is the number of breakthrough innovations by a firm each 
year, effectively acting as a measure of innovation quality. Similar to the analysis of patent-based 
metrics, the primary independent variable is M&A status (-3 to +5 years with respect to M&A 
events). Industry metrics and financial metrics are also included as controlling variables. Then, I 
run OLS linear regression analyses on the product introduction metrics against the independent 
and control variables with firm and year fixed effects. 
Results: 
Table 8 of the Appendix shows the changes in number of product introductions around 
M&A events. My results in general confirm with those derived from patent data. The coefficients 
for total product innovation in post-M&A years are generally not significant, but the coefficient 
values tend to be larger for post-M&A years, suggesting higher quantity of innovation compared 
to pre-M&A years. The change in breakthrough or novel innovation around M&A is shown in 
Table 9. The coefficient values for M&A status show a decreasing trend from three years before 
to five years after M&A, suggesting that the number of breakthrough innovations is significantly 
lower post-M&A compared to pre-M&A years. Therefore, this analysis confirms with patent-
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based results that innovation quantity tends to increase while quality tends to decline following 
M&A events.    
In addition, higher total assets and higher R&D expenditure relative to assets are 
associated with higher number of product introductions, suggesting that firms with more 
resources and more R&D investments tend to produce more innovations. In post-M&A years, all 
of the three industry metrics (sales concentration, turbulence, and geographic concentration) are 
in general negatively related to both total product introductions and breakthrough introductions.         
 
iv. Changes in innovation around IPO based on scientific publication metrics 
In this section, I explore the relationship between innovation performance and strategic 
activities based on the scientific publications of firms. For dependent variables, innovation 
quantity is measured by article count (number of articles published by a firm in a year), and 
innovation quality is measured in two ways – citation count (number of times each article is 
cited) and novelty score.  
The novelty score is calculated based on text mining of the abstract of each published 
scientific article. Following Wu, Lou, and Hitt (2019), I employ a bag-of-words model to 
identify non-stop words in the abstract of each article and calculate the age of each word by 
journal field. I first clean up my collection of words by removing punctuations, numbers, and 
stop words identified from the SMART stop-word list built into R’s text mining package. I then 
reduce my “bag” so that it only includes the words appearing at least 1% of the time. Table 10 
shows summary charts from text mining of the abstracts.   
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To calculate word age, I follow the method of Wu, Lou, and Hitt (2019) and define that a 
word has an age of zero on its first appearance in a particular journal field. If a word has 
appeared previously, then the word age is the difference between application date of the article 
and the time the word first appears. Based on the bag-of-word model, an article’s novelty score 
would be based on the average age of all non-stop words in the abstract. In order to avoid cases 
in which the age is zero, I add one to the age value. To obtain the novelty score of each article, I 
calculate the reciprocal of the scaled age of all non-stop words in the abstract and take the 
average of the reciprocal values as shown below. A firm’s novelty score is the average score of 
the entire set of its published articles in a given year. 
𝑁𝑜𝑣𝑒𝑙𝑡𝑦 =
1
𝑁
∑
1
𝐴𝑔𝑒𝑤 + 1
𝑁
𝑤=1
 
Table 11 shows the summary statistics of scientific publications of firms from three years 
before to five years after IPO events. My dataset contains 786 unique firms and 6,603 unique 
publications (2,135 with abstracts available). The publications are concentrated in Biology, 
Engineering, and Medicine fields. The average publication count in post-IPO years is higher than 
in pre-IPO years, while both the citation count and the abstract novelty score in post-IPO years 
are lower than the pre-IPO case.     
The primary independent variable is IPO status, which is a dummy variable that goes 
from -3 to +5, representing 3 years before to 5 years after an IPO event. Industry and financial 
metrics are also included as controlling variables. Then, I run OLS linear regression analyses on 
the scientific publication metrics against the independent variables with firm and year fixed 
effects. 
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Results: 
As shown in Table 12, innovation quantity (as measured by number of scientific article 
publications) in post-IPO years tends to be higher than in pre-IPO years, suggesting higher 
quantity of innovation post-IPO. Table 13 exhibits the change in the number of research 
collaborators, or article co-authors, around IPO and shows that the number of collaborators is 
significantly higher in post-IPO years than in pre-IPO years. This indicates that the increase in 
innovation quantity following an IPO process might be partially due to the increase in access to 
research collaborators and resources for firms.  
To examine the quality of innovation, I first look at the change in article citation count 
around IPO. As shown in Table 14, however, this analysis does not generate significant results, 
and the coefficient values from three years before to five years after IPO do not show a 
consistent pattern. In order to better examine innovation quality, I use the novelty score 
calculated from text mining of the abstracts of each article. Table 15 exhibits the change in firm-
level average novelty score around IPO. Similar to the citation count analysis based on patent 
data, the novelty scores in post-IPO years are significantly lower than those in pre-IPO years. In 
addition, in post-IPO status, industry metrics including sales concentration, turbulence, and 
geographic concentration correlate positively with the novelty score, although the coefficients 
lack significance.    
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v. Changes in innovation around M&A based on scientific publication metrics 
I repeat the publication-based OLS regression analysis for the M&A case. The dependent 
variables include publication count, collaborator count, average citation count, and average 
novelty score. The primary independent variable is M&A status, which is a dummy variable that 
goes from -3 to +5, representing 3 years before to 5 years after an M&A event. Industry and 
financial metrics are also included as controlling variables.  
My publication-M&A dataset contains 267 firms, 488 unique M&A transactions, and 
5,215 unique publications (3,797 with abstracts available). Table 16 in the Appendix exhibits 
summary statistics of scientific publications from three years before to five years after M&A 
transactions. The Biology, Engineering, and Computer Science sectors appear to have the 
greatest number of publications. In addition, the mean number of published articles is higher in 
post-M&A years compared to pre-M&A years. While the mean novelty score decreases in post-
M&A years, the average number of publication citations increases following M&A. 
Results: 
As shown in Table 17, results for innovation quantity (as measured by number of 
publications) are not significant but coefficient values do point to higher publication count in 
post-M&A years. Similar to the IPO case, firms tend to have more research collaborators post-
M&A, as exhibited in Table 18. 
I then proceed to analyze the change in article citation count around M&A and the 
regression results are shown in Table 19. Contrary to previous findings on innovation quality 
measured by citation count, the coefficient values for the average citation point to higher 
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innovation quality in post-M&A years, although most results are insignificant. Nevertheless, 
when the abstract novelty score is examined in Table 20, I find that the novelty score decreases 
following M&A transactions, and this is consistent with previous findings that innovation quality 
declines post-M&A. In addition, industry sales concentration and geographic concentration have 
significantly positive correlations with the novelty score in post-M&A status. All four financial 
metrics, including log total assets, net income to total assets, cash to total assets, R&D to total 
assets correlate positively with the novelty score despite the coefficients lacking significance, 
suggesting that firms with more competent resources, deployable capital, and R&D investments 
may show higher innovation quality.      
 
B. Innovator Mobility around IPO and M&A Events  
 
The series of OLS regression analysis discussed in part A generally show that innovation 
quantity increases while innovation quality decreases following IPO and M&A activities. The 
findings are consistent among patent-based, product-based, and publication-based metrics. In 
order to explain why innovation performance experiences these observed changes around IPO 
and M&A activities, I focus on analyzing innovator mobility as a potential reason. According to 
Bernstein (2015), key inventors may choose to leave or stay following an IPO or M&A event 
due to changes in organizational culture and incentive compensation plans.  
Following Bernstein (2015) who analyzes innovator mobility based on patent data, I 
utilize the Scopus database to examine the mobility of the authors of firms’ scientific 
publications. Since Scopus provides unique author identifiers, the authors can be classified into 
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three types. A “stayer” is defined as an author with at least a single paper before and after the 
IPO/M&A at the same firm; a “leaver” is defined as an author with at least a single paper at a 
sample firm before the IPO/M&A, and at least a single paper in a different company after the 
IPO/M&A; and a newcomer is defined as an author that has at least a single paper after the 
IPO/M&A event at a sample firm, but no papers before, and has at least a single paper at a 
different firm before the event. I attribute a publication equally to each author of the paper and 
compare the behavior of stayers, leavers, and newcomers from 3 years before to 5 years after 
IPO and M&A activities. 
 
i. Innovator mobility around IPO 
To explore the innovator mobility around IPO, I compare the innovation performance of 
stayers versus leavers during the three years before the IPO event, and the innovation 
performance of stayers versus newcomers during the five years after IPO. As shown in Table 21, 
the mean log publication count is used to compare the author-level innovation quantity, and the 
mean log citation and mean novelty score are used to compare the author-level innovation 
quality. The orange bars overlaid on the charts for each metric are error bars. For the author 
types to differ significantly in each innovation metric on average, the error bars must have no 
overlap.  
According to the charts in Table 21, stayers produce significantly more publications on 
average than leavers in pre-IPO years and significantly more publications on average than 
newcomers in post-IPO years. However, the quality of innovations produced by stayers, leavers, 
and newcomers is generally not significantly different, though newcomers on average produce 
publications with significantly higher citations than stayers. As a result, we may infer that the 
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increase in innovation quantity following IPO events might be partially explained by the ability 
of stayers to publish more articles post-IPO. However, we do not have sufficient evidence to 
propose that the post-IPO decline in firm-level innovation quality can be explained by the 
mobility of authors.  
 
ii. Innovator mobility around M&A 
I employ the same method on the publication-M&A dataset. As shown in Table 22, I 
compare the innovation performance of stayers versus leavers during the three years before the 
M&A event, and the innovation performance of stayers versus newcomers during the five years 
after M&A. I observe that stayers produce significantly more publications on average than 
leavers in pre-M&A years and significantly more publications on average than newcomers in 
post-M&A years.  
Measured by citation count, the quality of innovations produced by stayers is 
significantly lower than that of leavers in pre-M&A years and significantly lower than that of 
newcomers in post-M&A years. Measured by abstract novelty score, however, the quality of 
innovations produced by stayers is significantly higher than that of leavers in pre-M&A years but 
does not differ significantly from that of newcomers in post-M&A years.  
Therefore, the increase in innovation quantity following M&A events might also come 
from the higher number of innovations produced by stayers. For innovation quality, my results 
are contradictory. For example, stayers produce innovations with lower mean citation count but 
higher novelty score compared with leavers in pre-M&A years. As such, we are unable to obtain 
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consistent findings to show that the observed changes in firm-level innovation quality can result 
from author mobility. 
 
C. Case Studies on Innovation Novelty of Selected Firms around IPO and M&A 
Events   
 
According to the previous analyses based on abstract novelty of firms’ scientific 
publications, innovation novelty tends to decrease after firms go public or acquire another 
company. Nevertheless, the analysis of innovator mobility does not provide sufficient evidence 
on whether the decline in novelty can be explained by the change in the composition of 
innovators. While innovation novelty score is found to decrease on the aggregate level following 
IPO and M&A activities, certain firms may still be able to exhibit growing novelty despite 
undergoing an IPO and/or M&A. This section turns to individual cases of specific firms so as to 
examine potential reasons behind the changes in innovation novelty around IPO and M&A 
activities. 
 
i. Innovation Novelty Score of Cephalon Inc. around IPO  
Table 23 shows the changes in innovation novelty score of Cephalon Inc. in years around 
its IPO (1988-1996). Prior to its acquisition by Teva Pharmaceuticals in 2011, Cephalon was a 
global pharmaceutical company founded in 1987 and went public in 1991. According to the 
International Directory of Company Histories (2002), in its pre-IPO years (1987-1991), 
Cephalon was almost exclusively focused on scientific research, particularly on treatments for 
multiple sclerosis, strokes, and amyotrophic lateral sclerosis. Although Cephalon did not allocate 
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sufficient resources to developing its sales force and navigating clinical trials, the company was 
still able to raise funding from investors, secure collaboration contracts with established 
pharmaceutical firms, and make decent progress on scientific discoveries. Cephalon went public 
in 1991, but the market’s concern of the overvaluation of biotech stocks caused its stock price to 
drop below the IPO price. As such, the company was under shareholder pressure to generate 
revenues and earnings. Despite the pressure from the stock market, Cephalon continued its 
research efforts in the years following the IPO. In 1993, Cephalon acquired rights to develop and 
sell Provigil, a treatment for narcolepsy, from French company Laboratoire L. Lafon. In 1995, 
the fourth year after its IPO, Cephalon shifted away from exclusive focus on research to sales 
force development. In 2000, the company acquired product rights to Actiq, a cancer pain 
treatment approved by FDA in 1998, through merging with Anesta Corporation. The company 
later acquired rights to Gabitril, an epilepsy seizure treatment approved in 1997, from Abbot 
Laboratories.          
The changes in novelty score shown in Table 23 correspond to the crucial activities of 
Cephalon during the period around its 1991 IPO. Cephalon exhibited increasing innovation 
novelty in pre-IPO years due to its primary focus on R&D. Nevertheless, following its IPO, the 
company was faced with significant shareholder pressure to produce solid results, leading to a 
decline in innovation novelty. The novelty score recovered slightly from 1992 to 1994 because 
of Cephalon’s continued R&D investments in drug development but dropped again in 1995 as 
the company shifted away from exclusive research focus to building a sales force in order to 
generate revenues. In addition, the nature of the post-IPO innovation efforts at Cephalon appears 
to be more incremental than radical, as the rights to some of the most well-sold drugs (e.g., Actiq 
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and Gabitril) were acquired from other companies rather than owned by Cephalon from the 
initial development stage. 
 
ii. Innovation Novelty Score of Hospira Inc. around M&A  
Table 24 shows the change in innovation novelty score of Hospira Inc. in years around 
its 2006 M&A events (2004-2011). Hospira was created from the spin-off of the hospital 
products division of Abbot Laboratories in 2004. Before its acquisition by Pfizer in 2015, 
Hospira was a leading manufacturer of pharmaceutical injectables and medication management 
systems. According to the International Directory of Company Histories (2014), following its 
spin-off from Abbot, the company adopted an aggressive plan for increasing R&D investments. 
New products were developed and launched through both internal manufacturing improvement 
and acquisitions. In 2006, Hospira acquired Australian company BresaGen which developed 
peptides and proteins as well as another Australian company Mayne Pharma which enabled 
Hospira to become the world’s largest general injectable pharmaceuticals company. In the years 
following its 2006 acquisitions, Hospira maintained its focus on research and continued to 
introduce new products such as irinotecan hydrochloride (an oncology drug) and imipenem-
cilastatin (an antibiotic). The company also engaged in strategic collaborations such as a 
partnership with Bridge Medical to improve the medication management system.       
As Table 24 shows, Hospira experienced a generally increasing novelty trend post-
M&A, although the novelty score for firms on the aggregate level tends to decline following 
M&A activities. The spin-off from Abbot in 2004 enabled Hospira to concentrate resources in 
R&D spending, and the acquisition of BresaGen and Mayne Pharma in 2006 allowed Hospira to 
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expand internationally. Overall, it appears that Hospira was able to maintain consistent research 
momentum through a balanced mix of internal development, research collaborations, and 
acquisitions over its life cycle.  
 
iii. Innovation Novelty Score of Eastman Chemical Company around M&A  
Table 25 shows the change in innovation novelty score of Eastman Chemical Company 
in years around its 1999 M&A event (1996-2004). Created as a result of the spin-off from 
Eastman Kodak in 1994, Eastman Chemical is a global specialty chemical company that 
produces chemicals, fibers, and plastics materials. According to the International Directory of 
Company Histories (2011), Eastman Chemical focused on product innovation and globalization 
in the initial years after the spin-off in order to maintain a competitive edge in the chemicals 
market. In 1999, as part of its product innovation strategy, Eastman Chemical acquired Lawter 
International, a manufacturer of specialty products for ink and coatings. However, due to 
decreasing demand for chemicals products, Eastman was already faced with production 
overcapacity by 1997 and had to initiate a restructuring process to reduce operational costs. As a 
result, the company gradually shifted from product innovation to process innovation. For 
instance, Eastman set up system-to-system connections with trading partners and established a 
joint venture with Henderson China Holdings to launch e-commerce websites in China. In 2003, 
Eastman sold off parts of its coatings, adhesives, specialty polymers, and inks (CASPI) division 
which was underperforming and reduced workforce. Nevertheless, despite slightly better results 
through process innovation, the chemicals industry continued to be in a downturn in the early 
2000s.  
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The fluctuations in innovation novelty score in Table 25 seem to align with Eastman’s 
strategic decisions from 1996 to 2004. Focused on product innovation and globalization in the 
1990s, the company had limited room for generating highly novel innovation due to decreasing 
demand for chemicals products worldwide. As such, the company shifted from product 
innovation and production capacity improvement to process innovation. The switch to a different 
innovation area resulted in increasing innovation novelty, but the novelty score still dropped 
around 2003 due to the continued downturn of the chemicals industry. It appears that the changes 
in the novelty score of Eastman Chemical Company were more closely related to 
macroeconomic patterns than to the acquisition of Lawter International in 1999.     
 
iv. Innovation Novelty Score of Millennium Pharmaceuticals around IPO and M&A  
Table 26 shows the change in innovation novelty score of Millennium Pharmaceuticals 
Inc. in years around its 1996 IPO event and 1997 M&A event (1995-2002). Founded in 1993, 
Millennium Pharmaceuticals is a global pharmaceuticals company specializing in treatments for 
oncology, inflammation, and metabolic diseases. According to the International Directory of 
Company Histories (2002), Millennium engaged in R&D primarily through research 
collaborations. In 1994, the company signed strategic alliance with Hoffmann-La Roche to 
develop drugs that treat type II diabetes. In 1995, it established a joint venture with Eli Lilly to 
develop treatment for atherosclerosis and collaborated with Astra AB to target inflammatory 
diseases. Millennium went public in 1996 as its research efforts started to translate into tangible 
results. In 1997, Millennium acquired ChemGenics Pharmaceuticals which allowed the company 
to broaden its development of antibacterial drugs. In the following years, Millennium signed up 
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for more strategic alliances with collaborators including Bayer AG, Bristol-Myers Squibb, and 
Aventis SA. In 2001, Millennium acquired Cor Therapeutics via a stock swap and gained rights 
to cardiovascular drugs.    
As Table 26 shows, the innovation novelty score of Millennium Pharmaceuticals was in 
a declining trend following its 1996 IPO. The company pursued an innovation strategy based 
primarily on strategic collaborations and acquisitions. As such, the focus on collaborations and 
acquisitions as opposed to internal drug development may have caused innovation novelty to 
decline. 
Overall, according to the four case studies in this section, it appears that companies which 
can maintain strong R&D momentum through a balanced combination of internal development 
and strategic collaborations tend to achieve higher innovation novelty following IPO and M&A 
events. Nevertheless, as the Eastman Chemical case demonstrates, sometimes the changes in 
innovation novelty following an IPO or M&A might be more related to fluctuations in industry 
performance than to the IPO or M&A event specifically.  
 
 
5. Conclusion 
In this paper, I examine the change in firms’ innovation performance around IPO and 
M&A events based on metrics from three modes of innovation – patents, product introductions, 
and scientific publications. While scholars have primarily focused on only one innovation mode, 
I consider all three modes to comprehensively measure firms’ innovative activities. To assess the 
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quality of innovation, in addition to the citation count metric which has been widely used in the 
literature, I also consider the abstract novelty score in the case of scientific publications in order 
to conduct a more in-depth examination of the innovative content of each innovation. After 
examining a variety of innovation modes and metrics, I find that innovation quantity increases 
while innovation quality decreases following IPO and M&A events. The results are generally 
consistent among patent-based, product-based, and publication-based metrics, and confirm with 
the results from previous literature.  
In addition to exploring how innovation performance varies with IPO and M&A status, I 
also control for industry characteristics (sales concentration, turbulence, and geographic 
concentration) and firm-level financial metrics (total assets, net income to total assets, cash to 
total assets, and R&D to total assets). In general, higher sales concentration and geographic 
concentration relate to lower innovation quantity (number of innovations) in post-event years 
than in pre-event years, possibly due to reduced incentives to produce high quantity of 
innovations when the market in post-event years is more concentrated, barriers to entry are 
higher, and resources and collaborators are more reachable. However, higher sales concentration 
and geographic concentration tend to correlate with higher innovation quality (novelty of 
innovation) in post-event years than in pre-event years, possibly because firms have higher 
capacity to focus on generating economic value from truly novel innovations when the market in 
post-event years is more financially and geographically concentrated. As Feldman (1993) shows, 
“innovation is found to cluster geographically in areas which contain concentrations of 
specialized resources which enhance and facilitate the innovation process.” In terms of financial 
metrics, firms that exhibit larger asset and cash holdings, higher profitability, and more R&D 
investments are generally more innovative in terms of both quality and quantity.        
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Overall, despite the ability to produce more innovations after going public or acquiring 
another company, firms need to be mindful of the potential loss in innovation quality. Innovation 
is a long-term task crucial to a firm’s long-term performance, but firms might be subject to 
higher shareholder pressure once they go public or experience a change in the composition of 
major shareholders following an M&A. As such, firms may be pressured to satisfy short-term 
earnings at the expense of long-term performance. Although the study of innovator mobility in 
this paper does not provide sufficient insights on whether the changes in innovation performance 
around strategic events are explained by the changes in the composition of innovators, it is still 
reasonable to believe that the restructuring of the talent base following strategic events can exert 
substantial influence on a firm’s innovation capacity, whether positively or negatively. 
Moreover, the case studies on specific firms show that firms which can maintain innovation 
momentum through a balanced combination of internal development and strategic collaborations 
following IPO and M&A events tend to exhibit increasing novelty score, while companies that 
focus too much on generating revenues or pursue an unbalanced innovation strategy tend to 
experience declines in novelty. Therefore, it would be essential for firms to develop strategies to 
maintain and enhance innovation quality and avoid disruptions to innovative capacity.    
 
6. Discussion 
A. Significance  
 
This paper could be helpful to corporate strategy researchers and experts, especially those 
who focus on corporate innovation. Instead of restricting the measurement of innovation to 
patent-based metrics, the paper discusses alternative sources of innovation such as new scientific 
 
 
35 
publications and new product introductions and aims to improve the measurement of innovation 
quality through textual analysis of article abstracts. By proposing a more comprehensive measure 
of innovation performance, this paper could help future researchers to gain a more systematic 
understanding of innovation and open up new perspectives as they explore the innovative 
practices of firms and how they relate to various aspects of firm performance.  
The paper could also be relevant to firms as they attempt to continuously improve their 
innovation performance in order to achieve competitive advantages against their peers. For 
example, the proposed innovation novelty score should help firms to more accurately assess their 
innovation quality relative to their competitors. The findings on innovator mobility and the case 
studies on specific firms around IPO and M&A activities may also be useful as firms make their 
strategic decisions on whether to go public or engage in a merger or acquisition. 
       
 
B. Limitations and Ideas for Future Work  
This research contains some limitations as well. First, when analyzing the change in 
innovation around M&A events, I only include M&A transactions involving public acquirers, as 
most target firms would disappear following an acquisition. However, some target firms may 
remain as separate subsidiaries of their corresponding acquirer firms after acquisitions, so some 
patents may be assigned to the target firm rather than to the acquirer firm, despite the fact that 
the innovation comes from the acquirer firm as a whole. As such, this analysis may 
underestimate the innovation output following M&A events. Nevertheless, simply adding the 
patents of post-acquisition target firms to the set of patents from the parent firms would not work 
as the Thomson SDC database only contains M&A transactions involving public firms. Some 
 
 
36 
public parent firms may have acquired private subsidiary firms that operate as a standalone entity 
in the US patent system and do not show up in the patent database. In order to mitigate the 
underestimation problem, it would be better to utilize a database that contains M&A transactions 
involving both public and private firms so that private acquirers and targets are not excluded 
from the analysis. 
Second, the regression analyses on within-firm variations in innovation performance are 
endogenous in itself and prone to self-selection bias. According to Bernstein (2015), firms may 
choose to go public at a specific stage in their respective life cycle. For example, firms might be 
more likely to go public when they have achieved highly novel innovations, so the regression to 
measure how innovation relates to IPO status might be subject to the effect of life cycle as a 
confounding variable. In addition, my results are primarily based on OLS linear regression 
analysis, so I have only established relationships between innovation performance and IPO or 
M&A status. In order to examine whether the post-event increase in innovation quantity and 
decrease in innovation quality are indeed caused by the strategic event itself, I would need to 
compare the innovation of firms that underwent the event with that of similar firms that did not. 
Hence, in future work, I could follow Bernstein (2015) to compare the post-IPO innovation 
performance of firms that actually went public with that of similar firms that filed for IPO but 
did not go public eventually. The same method would apply to the M&A case.     
Third, my calculation of the novelty score for scientific publications might also contain 
algorithmic errors. Because Scopus does not contain unique identifiers for firm names, I 
manually input firm names into Scopus’ web search query to download basic publication 
information and then match the firm names in the downloaded data to GVKEY identifiers. 
Because there might be multiple variations of a firm’s name, the matching process may be crude 
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and incomplete. In addition, in order to focus on only innovative words in the abstract text-
mining analysis, I remove the stop words identified by the SMART information retrieval system. 
Nevertheless, the removal process might not be exhaustive and there might be certain 
commonly-used words or phrases that should not be considered as innovative content. In future 
work, instead of applying a built-in stop-word list such as SMART, I would need to conduct an 
analysis on Term Frequency–Inverse Document Frequency (TF-IDF) to investigate how 
important each abstract word is to the scientific publications in my collection. In this way, I 
could effectively remove words that are not novel enough in scientific research. 
Fourth, I have been able to analyze the three innovation modes (patents, product 
introductions, and scientific publications) separately in this paper, but the observed relationships 
could be verified in the future through exploring all three innovation modes collectively to 
analyze the association and causation between overall firm innovation and strategic activities. 
According to Murray and Stern (2007), scientific publications tend to pre-date patent grants and 
publication citations tend to decline following patent grants. Therefore, one potential way to 
consolidate patents and publications is to place a higher weight on publication-based metrics 
prior to patent grant and a higher weight on patent-based metrics after the patent grant. This 
approach should help researchers to obtain a more comprehensive understanding of firm 
innovation.  
Last but not the least, as employee mobility increases and information exchange becomes 
more convenient, companies have been transitioning from an internal and closed innovation 
strategy to a combination of internal development and open innovation. Scholars have 
demonstrated that an open innovation process facilitates innovators to adopt a solution-seeking 
mindset and focus on the big picture of why an innovation is needed (Lifshitz-Assaf, Tushman, 
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and Lakhani 2018). Open innovation is also found to broaden a firm’s knowledge and expertise 
by enabling the firm to venture into new technological areas and strengthen existing areas that 
are still insufficient (Shin et al. 2017). However, while firms may intend to source distant 
knowledge through open innovation, the process of sourcing external ideas might actually 
narrow their perspective as they are more likely to focus on knowledge areas that are more 
familiar to them (Piezunka and Dahlander 2015).  
In this research paper, I investigate how firm innovation as a whole changes around IPO 
and M&A activities but do not distinguish between closed and open innovation. In order to 
contribute to the field of research on open innovation, I could expand the scope of this paper by 
analyzing how the performance of open innovation changes around firms’ IPO and M&A 
activities. One approach would be to analyze the change in collaboration pattern around IPO and 
M&A events. Following Belderbos et al. (2014), I can classify the collaborators of each patent or 
scientific publication into intra-industry partners or competitors, inter-industry partners or 
complementors, and universities. Then, I would explore the change in the composition of 
collaborators around IPO and M&A and how the collaboration pattern relates to the quantity and 
quality of open innovation. In addition, I could also calculate an “innovation openness ratio” for 
each firm based on the framework proposed by Michelino et al. (2015) and examine how the 
openness ratio fluctuates around IPO and M&A events. A third way of measuring open 
innovation could be based on a firm’s usage of open source software in its innovative activities 
(Nagle 2018). The study of how open innovation relates to IPO and M&A events should provide 
insights into whether enhanced access to financial and strategic resources following an IPO or 
M&A event would enable a firm to enhance the scale and quality of its open innovation efforts.   
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Appendix 
Table 1. Summary Statistics of Patent-IPO Dataset 
This table displays summary statistics of the patent applications of firms from three years before 
to five years after going public. Section A displays the distribution of patent applications across 6 
major tech classes. Sections B and C show the average innovation measures during 3 years 
before IPO and during 5 years after IPO, respectively. Section D lists the IPO filing, patent 
applications, and patent grants by year.     
 
 
Section A – Distribution of patents across 6 major tech classes 
 
    
 
Section B – Average innovation measures during 3 years before IPO 
 
 
 
Section C – Average innovation measures during 5 years after IPO 
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Section D – IPO Filing, Patent Applications, and Patent Grants by Year 
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Table 2. Within-Firm Change in Patent Count around IPO 
This table shows the changes in patent count around IPO. I use the natural logarithm of the 
patent count to reduce skewness in the data. To avoid any zero values, I add one to the patent 
count when taking the natural logarithm. The regression in Column (1) only considers IPO status 
dummies. Column (2) adds industry metrics, including sales concentration (HHI), turbulence, 
and geographic concentration (EGI), as well as their interactions with post-IPO status. Column 
(3) adds four additional variables on financial metrics: log total assets, net income / total assets, 
cash / total assets, and R&D / total assets.    
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Table 3. Within-Firm Change in Patent Quality Metrics around IPO 
This table shows the changes in three patent quality metrics around IPO. I use the natural 
logarithm of the citation count to reduce skewness in the data. To avoid any zero values, I add 
one to the citation count when taking the natural logarithm. Column (1) shows the change in 
average log citation count, Column (2) shows the change in average generality (degree to which 
a patent is cited by patents from a more diverse range of technology classes), and Column (3) 
shows the change in average originality (degree to which a patent is citing a broader set of 
technology classes). Independent variables include IPO status dummies, industry metrics (sales 
concentration HHI, turbulence, and geographic concentration EGI), and their interactions with 
post-IPO status.  
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Table 4. Summary Statistics of Patent-M&A Dataset 
This table displays summary statistics of the patent applications of firms from three years before 
to five years after M&A transactions. Section A displays the distribution of patent applications 
across 6 major tech classes. Sections B and C show the average innovation measures during 3 
years before M&A and during 5 years after M&A, respectively. Section D lists the M&A deals, 
patent applications, and patent grants by year.     
 
 
Section A – Distribution of patents across 6 major tech classes 
 
    
 
Section B – Average innovation measures during 3 years before M&A 
 
 
 
Section C – Average innovation measures during 5 years after M&A 
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Section D – M&A Deals, Patent Applications, and Patent Grants by Year 
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Table 5. Within-Firm (Acquirer) Change in Patent Count around M&A 
This table shows the changes in patent count around M&A for acquirers. I use the natural 
logarithm of the patent count to reduce skewness in the data. To avoid any zero values, I add one 
to the patent count when taking the natural logarithm. The regression in Column (1) only 
considers M&A status dummies. Column (2) adds industry metrics, including sales concentration 
(HHI), turbulence, and geographic concentration (EGI), as well as their interactions with post-
M&A status. Column (3) adds four additional variables on financial metrics: log total assets, net 
income / total assets, cash / total assets, and R&D / total assets.    
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Table 6. Within-Firm (Acquirer) Change in Patent Quality Metrics around M&A 
This table shows the changes in three patent quality metrics around M&A for acquirers. I use the 
natural logarithm of the citation count to reduce skewness in the data. To avoid any zero values, I 
add one to the citation count when taking the natural logarithm. Column (1) shows the change in 
log average citation count, Column (2) shows the change in average generality (degree to which 
a patent is cited by a more technologically varied array of patents), and Column (3) shows the 
change in average originality (degree to which a patent is citing a broader array of technology 
classes). Independent variables include M&A status dummies, industry metrics (sales 
concentration HHI, turbulence, and geographic concentration EGI), and their interactions with 
post-M&A status.  
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Table 7. Summary Statistics of Product-M&A Dataset 
This table displays summary statistics of the product introductions of firms from three years 
before to five years after M&A transactions. Section A displays the distribution of product 
introductions across 7 major product sectors. Sections B and C show the average innovation 
measures during 3 years before M&A and during 5 years after M&A, respectively. Section D 
lists the M&A deals and total product introductions by year.     
 
Section A – Distribution of product introductions across 7 major product sectors 
 
    
 
Section B – Average innovation measures during 3 years before M&A 
 
 
 
Section C – Average innovation measures during 5 years after M&A 
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Section D – M&A Deals and Total Product Introductions by Year 
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Table 8. Within-Firm Change in Total Product Introductions around M&A 
This table shows the changes in total product count around M&A for acquirers. I use the natural 
logarithm of the total product count to reduce skewness in the data. To avoid any zero values, I 
add one to the product count when taking the natural logarithm. The regression in Column (1) 
only considers M&A status dummies. Column (2) adds industry metrics, including sales 
concentration (HHI), turbulence, and geographic concentration (EGI), as well as their 
interactions with post-M&A status. Column (3) adds four additional variables on financial 
metrics: log total assets, net income / total assets, cash / total assets, and R&D / total assets.    
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Table 9. Within-Firm Change in Breakthrough Product Introductions around 
M&A 
This table shows the changes in breakthrough product count around M&A for acquirers. I use the 
natural logarithm of the breakthrough product count to reduce skewness in the data. To avoid any 
zero values, I add one to the product count when taking the natural logarithm. The regression in 
Column (1) only considers M&A status dummies. Column (2) adds industry metrics, including 
sales concentration (HHI), turbulence, and geographic concentration (EGI), as well as their 
interactions with post-M&A status. Column (3) adds four additional variables on financial 
metrics: log total assets, net income / total assets, cash / total assets, and R&D / total assets.    
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Table 10. Summary Charts from Abstract Text-Mining 
This table displays summary charts from text mining of the words in the abstracts of the 
scientific articles published by firms. Section A displays the 20 most commonly-used words in 
abstracts and their respective frequencies. Some words appear to be incomplete because I have 
stemmed each word (removed any inflectional affixes in each word) in order to ensure that all 
forms of each word have been captured. Section B shows a word cloud generated from the set of 
stemmed words, with visually larger words being more common.           
 
 
 
Section A – The 20 Most Common Words in the Abstracts of Scientific Publications 
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Section B – Word Cloud  
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Table 11. Summary Statistics of Publication-IPO Dataset 
This table displays summary statistics of the scientific article publications of firms from three 
years before to five years after IPO. Section A displays the distribution of scientific publications 
across 9 major journal fields. Sections B and C show the average innovation measures during 3 
years before IPO and during 5 years after IPO, respectively. Section D lists the IPO filings and 
total scientific publications by year. 
 
 
Section A – Distribution of scientific publications across 9 major journal fields 
 
 
 
Section B – Average innovation measures during 3 years before IPO 
 
 
 
Section C – Average innovation measures during 5 years after IPO 
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Section D – IPO Filings and Scientific Publications by Year 
 
 
 
 
 
  
 
 
60 
Table 12. Within-Firm Change in Publication Count around IPO 
This table shows the changes in scientific publication count around IPO. I use the natural 
logarithm of the publication count to reduce skewness in the data. To avoid any zero values, I 
add one to the publication count when taking the natural logarithm. The regression in Column (1) 
only considers IPO status dummies. Column (2) adds industry metrics, including sales 
concentration (HHI), turbulence, and geographic concentration (EGI), as well as their 
interactions with post-IPO status. Column (3) adds four additional variables on financial metrics: 
log total assets, net income / total assets, cash / total assets, and R&D / total assets. In the output 
of the regression analysis, the interaction items are omitted because they have been dropped by 
the model due to rank deficiency.  
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Table 13. Within-Firm Change in Collaborator Count around IPO 
This table shows the changes in research collaborator count (number of collaborators/co-authors 
of each paper) around IPO. I use the natural logarithm of the collaborator count to reduce 
skewness in the data. To avoid any zero values, I add one to the collaborator count when taking 
the natural logarithm. The regression in Column (1) only considers IPO status dummies. Column 
(2) adds industry metrics, including sales concentration (HHI), turbulence, and geographic 
concentration (EGI), as well as their interactions with post-IPO status. Column (3) adds four 
additional variables on financial metrics: log total assets, net income / total assets, cash / total 
assets, and R&D / total assets. In the output of the regression analysis, the interaction items are 
omitted because they have been dropped by the model due to rank deficiency.  
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Table 14. Within-Firm Change in Citation Count around IPO 
This table shows the changes in average publication citation count around IPO. I use the natural 
logarithm of the average citation count to reduce skewness in the data. To avoid any zero values, 
I add one to the average citation count when taking the natural logarithm. The regression in 
Column (1) only considers IPO status dummies. Column (2) adds industry metrics, including 
sales concentration (HHI), turbulence, and geographic concentration (EGI), as well as their 
interactions with post-IPO status. Column (3) adds four additional variables on financial metrics: 
log total assets, net income / total assets, cash / total assets, and R&D / total assets. In the output 
of the regression analysis, the interaction items are omitted because they have been dropped by 
the model due to rank deficiency. 
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Table 15. Within-Firm Change in Novelty Score around IPO 
This table shows the changes in average novelty score around IPO. The regression in Column (1) 
only considers IPO status dummies. Column (2) adds industry metrics, including sales 
concentration (HHI), turbulence, and geographic concentration (EGI), as well as their 
interactions with post-IPO status. Column (3) adds four additional variables on financial metrics: 
log total assets, net income / total assets, cash / total assets, and R&D / total assets.  
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Table 16. Summary Statistics of Publication-M&A Dataset 
This table displays summary statistics of the scientific article publications of firms from three 
years before to five years after M&A transactions. Section A displays the distribution of 
scientific publications across 9 major journal fields. Sections B and C show the average 
innovation measures during 3 years before M&A and during 5 years after M&A, respectively. 
Section D lists the M&A transactions and total scientific publications by year.     
 
 
Section A – Distribution of scientific publications across 9 major journal fields 
 
 
 
Section B – Average innovation measures during 3 years before M&A 
 
 
 
Section C – Average innovation measures during 5 years after M&A 
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Section D – M&A Deals and Scientific Publications by Year 
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Table 17. Within-Firm Change in Publication Count around M&A 
This table shows the changes in scientific publication count around M&A. I use the natural 
logarithm of the publication count to reduce skewness in the data. To avoid any zero values, I 
add one to the publication count when taking the natural logarithm. The regression in Column (1) 
only considers M&A status dummies. Column (2) adds industry metrics, including sales 
concentration (HHI), turbulence, and geographic concentration (EGI), as well as their 
interactions with post-M&A status. Column (3) adds four additional variables on financial 
metrics: log total assets, net income / total assets, cash / total assets, and R&D / total assets. In 
the output of the regression analysis, the interaction items are omitted because they have been 
dropped by the model due to rank deficiency.  
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Table 18. Within-Firm Change in Collaborator Count around M&A 
This table shows the changes in research collaborator count (number of collaborators/co-authors 
of each paper) around M&A. I use the natural logarithm of the collaborator count to reduce 
skewness in the data. To avoid any zero values, I add one to the collaborator count when taking 
the natural logarithm. The regression in Column (1) only considers M&A status dummies. 
Column (2) adds industry metrics, including sales concentration (HHI), turbulence, and 
geographic concentration (EGI), as well as their interactions with post-M&A status. Column (3) 
adds four additional variables on financial metrics: log total assets, net income / total assets, cash 
/ total assets, and R&D / total assets. In the output of the regression analysis, the interaction 
items are omitted because they have been dropped by the model due to rank deficiency.  
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Table 19. Within-Firm Change in Citation Count around M&A 
This table shows the changes in average publication citation count around M&A. I use the 
natural logarithm of the average citation count to reduce skewness in the data. To avoid any zero 
values, I add one to the average citation count when taking the natural logarithm. The regression 
in Column (1) only considers M&A status dummies. Column (2) adds industry metrics, 
including sales concentration (HHI), turbulence, and geographic concentration (EGI), as well as 
their interactions with post-M&A status. Column (3) adds four additional variables on financial 
metrics: log total assets, net income / total assets, cash / total assets, and R&D / total assets. In 
the output of the regression analysis, the interaction items are omitted because they have been 
dropped by the model due to rank deficiency. 
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Table 20. Within-Firm Change in Novelty Score around M&A 
This table shows the changes in average novelty score around M&A. The regression in Column 
(1) only considers M&A status dummies. Column (2) adds industry metrics, including sales 
concentration (HHI), turbulence, and geographic concentration (EGI), as well as their 
interactions with post-M&A status. Column (3) adds four additional variables on financial 
metrics: log total assets, net income / total assets, cash / total assets, and R&D / total assets.  
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Table 21. Innovator Mobility around IPO 
This table displays comparisons of mean publication count, mean citation count, and mean 
novelty score of three types of innovators around IPO. A stayer is an author with at least a single 
paper before and after the IPO at the same firm; a leaver is an author with at least a single paper 
at a sample firm before the IPO, and at least a single paper in a different company after the IPO; 
a newcomer is an author that has at least a single paper after the IPO event at a sample firm, but 
no papers before, and has at least a single paper at a different firm before the event. Section A 
displays the comparisons between stayers and leavers during the three years before IPO. Section 
B displays the comparisons between stayers and newcomers during the five years after IPO.       
 
 
Section A – Stayers vs. Leavers in pre-IPO years 
 
 
 
 
  
 
 
  
 
 
 
 
Section B – Stayers vs. Newcomers in post-IPO years 
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Table 22. Innovator Mobility around M&A 
This table displays comparisons of mean log publication count, mean log citation count, and 
mean novelty score of three types of innovators around M&A. A stayer is an author with at least 
a single paper before and after the M&A at the same firm; a leaver is an author with at least a 
single paper at a sample firm before the M&A, and at least a single paper in a different company 
after the M&A; a newcomer is an author that has at least a single paper after the M&A event at a 
sample firm, but no papers before, and has at least a single paper at a different firm before the 
event. Section A displays the comparisons between stayers and leavers during the three years 
before M&A. Section B displays the comparisons between stayers and newcomers during the 
five years after M&A.   
 
Section A – Stayers vs. Leavers in pre-M&A years 
 
 
 
 
 
  
 
 
  
 
 
 
 
Section B – Stayers vs. Newcomers in post-M&A years 
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Table 23. Innovation Novelty Score of Cephalon Inc. around IPO   
This chart shows the change in innovation novelty score of Cephalon Inc. in years around its 
1991 IPO (from 1988 to 1996). The novelty score is calculated based on the average age of non-
stop words in the abstract of each article by journal field. The red dashed line indicates that 
Cephalon went public in year 1991.      
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Table 24. Innovation Novelty Score of Hospira Inc. around M&A   
This chart shows the change in innovation novelty score of Hospira Inc. in years around its 2006 
M&A events (from 2004 to 2011). The novelty score is calculated based on the average age of 
non-stop words in the abstract of each article by journal field. The red dashed line indicates that 
Hospira acquired BresaGen Ltd. and Mayne Pharma in 2006.  
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Table 25. Innovation Novelty Score of Eastman Chemical Co. around M&A   
This chart shows the change in innovation novelty score of Eastman Chemical Co. in years 
around its 1999 M&A event (from 1996 to 2004). The novelty score is calculated based on the 
average age of non-stop words in the abstract of each article by journal field. The red dashed line 
indicates that Eastman Chemical acquired Lawter International Inc. in 1999.  
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Table 26. Innovation Novelty Score of Millennium Pharmaceuticals Inc. around IPO 
and M&A   
This chart shows the change in innovation novelty score of Millennium Pharmaceuticals Inc. in 
years around its 1996 IPO event and 1997 M&A event (from 1995 to 2002). The novelty score is 
calculated based on the average age of non-stop words in the abstract of each article by journal 
field. The blue dashed line indicates that Millennium Pharmaceuticals went public in 1996. The 
red dashed line indicates that Millennium Pharmaceuticals acquired ChemGenics 
Pharmaceuticals Inc. in 1997.  
 
 
 
 
 
 
 
 
 
 
